Myriad Genetics (NASDAQ: MYGN) agreed to pay $375 million to acquire privately held Counsyl, Inc., which operates a high-complexity clinical laboratory dedicated to women’s health.
Counsyl’s lab services include carrier and non-invasive prenatal screening, including its Foresight Carrier Screen, Prelude Prenatal Screen, Reliant Cancer Screen, as well as supporting services through Counsyl Complete, a suite of solutions that integrate Counsyl screening into clinical workflows and patients’ lives.
Since the company’s founding, Counsyl has championed key advances in screening for women and their families, screening more than 850,000 patients, serving more than 17,000 healthcare providers, and providing more than 60,000 genetic counseling sessions.
Counsyl has experienced rapid growth, and in the last 12 months has performed over 280,000 reproductive genetic tests. Upon acquisition, Counsyl will become a wholly-owned subsidiary of Myraid. The deal is expected to close in the first quarter of 2019.
In November 2017, Counsyl announced it had received $80 million in financing from Perceptive Advisors, a New York-based life sciences investment firm, and the addition of Lily Sarafan, chief executive officer of Home Care Assistance (HCA), to the company’s board of directors.
